Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System
作者： Rachel Stevens , Imad Almanaseer , Miguel Gonzalez , Derin Caglar , Ryan A. Knudson
DOI: 10.2353/JMOLDX.2007.060102
关键词:
摘要: The HER2 gene, amplified in 10 to 35% of invasive human breast carcinomas, has prognostic and therapeutic implications. Fluorescent situ hybridization is one method currently used for assessing status, but fluorescent involves the time-consuming step manual signal enumeration. To address this issue, Vysis developed an automated enumeration system, AutoVysion. A multicenter, blinded study was conducted on 39 formalin-fixed, paraffin-embedded carcinoma specimens, including 20 nonamplified 19 (weakly highly amplified), provided duplicate each site analysis. Calculation HER2/CEP17 ratio hands-on time both approaches were compared. Overall agreement classification results (positive negative) 92.5% (196 212). AutoVysion System requires cases with scanner within range 1.5 3.0. When data are excluded, between 98.8% (169 171). average per slide 4.59 versus 7.47 minutes (savings 2.88 minutes/slide). These suggest that can correctly classify specimens may increase overall efficiency testing.
jmdjournal.org
unirioja.es
elsevier.com参考文章(31)
Lise Mette Gjerdrum, Boe Sandahl Sorensen, Eigil Kjeldsen, Flemming Brandt Sorensen, Ebba Nexo, Stephen Hamilton-Dutoit, Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma The Journal of Molecular Diagnostics. ,vol. 6, pp. 42- 51 ,(2004) , 10.1016/S1525-1578(10)60490-4
Luis Alberto Rubio-Martinez, José Maria Vera-Roman, Comparative assays for the HER-2/neu oncogene status in breast cancer. Archives of Pathology & Laboratory Medicine. ,vol. 128, pp. 627- 633 ,(2004) , 10.1043/1543-2165(2004)128<627:CAFTNO>2.0.CO;2
David G. Hicks, Raymond R. Tubbs, Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathology. ,vol. 36, pp. 250- 261 ,(2005) , 10.1016/J.HUMPATH.2004.11.010
José Baselga, Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials Oncology. ,vol. 61, pp. 14- 21 ,(2001) , 10.1159/000055397
M Bilous, C Ades, J Armes, J Bishop, R Brown, B Cooke, M Cummings, G Farshid, A Field, A Morey, P McKenzie, W Raymond, P Robbins, L Tan, Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. The Breast. ,vol. 12, pp. 92- 98 ,(2003) , 10.1016/S0960-9776(02)00273-4
Edith A. Perez, Patrick C. Roche, Robert B. Jenkins, Carol A. Reynolds, Kevin C. Halling, James N. Ingle, Lester E. Wold, HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization Mayo Clinic Proceedings. ,vol. 77, pp. 148- 154 ,(2002) , 10.4065/77.2.148
Martine Piccart, Caroline Lohrisch, Angelo Di Leo, Denis Larsimont, The Predictive Value of HER2 in Breast Cancer Oncology. ,vol. 61, pp. 73- 82 ,(2001) , 10.1159/000055405
Anna M. Bofin, Borgny Ytterhus, Cara Martin, John J. O’Leary, Bjørn M. Hagmar, Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. American Journal of Clinical Pathology. ,vol. 122, pp. 110- 119 ,(2004) , 10.1309/8A2DJFT07NE6EWHE
Douglas Harrington, Kenneth Bloom, Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. American Journal of Clinical Pathology. ,vol. 121, pp. 620- 630 ,(2004) , 10.1309/Y73U-8X72-B68T-MGH5
Hadi Yaziji, HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA. ,vol. 291, pp. 1972- 1977 ,(2004) , 10.1001/JAMA.291.16.1972